Patient One-Year Mortality Rate 5.6% with BVA-Guided Care Compared to 36.8% in Control Group –
Data Presented at Key Scientific Meeting
Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE: DXR), the worldwide chief in blood quantity measurement know-how, at the moment proclaims new knowledge validating the advantages of the Company’s BVA-100 blood check for coronary heart failure sufferers. Data have been introduced on the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which introduced collectively the world’s main consultants in coronary heart failure from September thirtieth via October third, 2022, in Washington, DC.
Jonathan Feldschuh, Chief Scientific Officer said, “This study shows the substantial benefit of BVA-guided care for Medicare patients with heart failure. Reducing the mortality rate by 81% on a 30-day basis and 85% on a one-year basis (from 36.8% to 5.6%) for one of the leading causes of death in the U.S. has been shown to be attainable with BVA in this 216 patient study. The study also showed a 56% lower rate of 30-day rehospitalization which points to a strong economic benefit for payers.”
“Understanding the impact of treatment decisions on outcomes for the over-65 population is of relevance to U.S. healthcare, as decisions made by the Centers for Medicare & Medicaid Services (CMS) regarding reimbursement, outcome-based incentives and penalties applied to health providers, and indication guidelines have enormous impact on how healthcare is provided,” mentioned John E. Strobeck, M.D., PhD, principal investigator.
The examine titled “Heart Failure Outcomes with Volume-guided Management in an Over-65 Population” confirmed this cohort of sufferers skilled markedly higher outcomes vs. controls for 30-day readmissions (12.0% vs 27.0%, P< .001), 30-day mortality (2.3% vs 11.8%, P< .001), and 365-day mortality (5.6% vs 36.8%, P< .001) charges.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the worldwide chief in blood quantity measurement know-how targeted on blood quantity testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the one diagnostic blood check cleared by the FDA to supply secure, correct, goal quantification of blood quantity standing and composition in comparison with patient-specific norms. Over 60,000+ assessments have been carried out at main hospital facilities throughout the U.S., enhancing hospital efficiency metrics in a broad vary of surgical and medical situations, together with considerably lowering mortality and readmissions in coronary heart failure and demanding care. Daxor has a number of ongoing multicenter trials within the areas of COVID-19 and coronary heart failure remedy with assist from the NIH and is beneath contract growing analyzers to enhance fight casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimum fluid administration with blood quantity evaluation. Daxor’s imaginative and prescient is perfect blood quantity for all. For extra data, please go to our web site at Daxor.com.
Forward-Looking Statements
Certain statements on this launch might embrace forward-looking statements throughout the which means of the Private Securities Litigation Reform Act of 1995, together with with out limitation, statements relating to the influence of hiring gross sales employees and enlargement of our distribution channels. Forward-looking statements are predictions, projections and different statements about future occasions which can be based mostly on present expectations and assumptions and, in consequence, are topic to dangers and uncertainties. Many components might trigger precise future occasions to vary materially from the forward-looking statements on this launch, together with, with out limitation, these danger related to our post-market scientific knowledge assortment actions, advantages of our merchandise to sufferers, our expectations with respect to product growth and commercialization efforts, our skill to extend market and doctor acceptance of our merchandise, probably aggressive product choices, mental property safety, FDA regulatory actions, our skill to combine acquired companies, our expectations relating to anticipated synergies with and advantages from acquired companies, and extra different dangers and uncertainties described in our filings with the SEC. Forward-looking statements converse solely as of the date when made. Daxor doesn’t assume any obligation to publicly replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
[email protected]
